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Background: Confirmation of artemisinin-delayed parasite clearance in Plasmodium falciparum along the
Thai-Myanmar border has inspired a global response to contain and monitor drug resistance to avert the disastrous
consequences of a potential spread to Africa. However, resistance data from Myanmar are sparse, particularly from
high-risk areas where limited health services and decades of displacement create conditions for resistance to
spread. Subclinical infections may represent an important reservoir for resistance genes that confer a fitness
disadvantage relative to wild-type alleles. This study estimates the prevalence of resistance genotypes in three
previously unstudied remote populations in Myanmar and tests the a priori hypothesis that resistance gene
prevalence would be higher among isolates collected from subclinical infections than isolates collected from febrile
clinical patients. A systematic review of resistance studies is provided for context.
Methods: Community health workers in Karen and Kachin States and an area spanning the Indo-Myanmar border
collected dried blood spots from 988 febrile clinical patients and 4,591 villagers with subclinical infection
participating in routine prevalence surveys. Samples positive for P. falciparum 18 s ribosomal RNA by real-time PCR
were genotyped for P. falciparum multidrug resistance protein (pfmdr1) copy number and the pfcrt K76T
polymorphism using multiplex real-time PCR.
Results: Pfmdr1 copy number increase and the pfcrt K76 polymorphism were determined for 173 and 269 isolates,
respectively. Mean pfmdr1 copy number was 1.2 (range: 0.7 to 3.7). Pfmdr1 copy number increase was present in
17.5%, 9.6% and 11.1% of isolates from Karen and Kachin States and the Indo-Myanmar border, respectively. Pfmdr1
amplification was more prevalent in subclinical isolates (20.3%) than clinical isolates (6.4%, odds ratio 3.7, 95%
confidence interval 1.1 - 12.5). Pfcrt K76T prevalence ranged from 90-100%.
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Conclusions: Community health workers can contribute to molecular surveillance of drug resistance in remote
areas of Myanmar. Marginal and displaced populations under-represented among previous resistance investigations
can and should be included in resistance surveillance efforts, particularly once genetic markers of
artemisinin-delayed parasite clearance are identified. Subclinical infections may contribute to the epidemiology of
drug resistance, but determination of gene amplification from desiccated filter samples requires further validation
when DNA concentration is low.
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Genetically determined artemisinin-delayed parasite
clearance or tolerance, first documented on the Thai-
Cambodia border, has emerged on the border of Thailand
and Myanmar [1,2]. Recently published estimates of malaria
mortality trends suggest that the previous spread of chloro-
quine (CQ) and sulphadoxine-pyrimethamine resistance
from Southeast Asia to Africa [3,4] contributed to the large
increase in malaria mortality from 1980–2004 [5], and
spread of delayed parasite clearance to Africa would rep-
resent a global health catastrophe [6].
In recognition of Myanmar’s central location between
Southeast Asia and Africa, the WHO outlined a country-
specific strategy for Myanmar Artemisinin Resistance
Containment (MARC) [7]. The MARC surveillance
strategy calls for therapeutic efficacy studies and day-3,
parasite-positivity monitoring of artemisinin combination
therapy (ACT) in over 20 locations. However, a strategy
is lacking to assess drug resistance in remote populations
of Myanmar that government and international NGO
services have difficulty reaching.
Although molecular markers of artemisinin resistance
or delayed parasite clearance have yet to be identified,
tracking markers of resistance to partner drugs provides a
valuable tool to inform coformulation policy and monitor
progress of the Global Plan for Artemisinin Containment
(GPARC) and MARC. Clinical and parasitological failure
after treatment with an ACT is partially determined by
the local efficacy of non-artemisinin partner drugs [8].
Furthermore, the decreased parasiticidal effect of artemi-
sinin along the Myanmar-Thai border places greater reli-
ance on partner drugs. Tracking Plasmodium falciparum
multidrug resistance protein (pfmdr1) gene copy number
(CN) has become an important surveillance tool, particu-
larly in populations receiving artesunate-mefloquine.
Pfmdr1 CN is associated with delayed response to ACT,
including artesunate-mefloquine [9] and artemether–
lumefantrine [10,11], as well as resistance to multiple
monotherapy including mefloquine [12-15].
Molecular strategies are particularly valuable for sur-
veillance in remote, displaced and conflict-affected popu-
lations facing security and logistical constraints that
make conventional in vivo or in vitro resistance studiesimpractical [16]. Village health workers (VHWs) trained
by local community-based organizations play a key role
delivering malaria control services in hard-to-access
areas of Myanmar [17-19] emerging from decades of
conflict, but community based organizations and VHWs
have not contributed to past resistance surveillance efforts.
Recent studies successfully estimated pfmdr1 (CN) using
blood samples collected on filter paper [20], and this sim-
plified protocol makes it possible to extend the quantita-
tive assessment of gene copy number to remote settings
lacking the capacity for storage and transport of whole
or fractionated blood products.
One question of potential importance in resistance con-
tainment is the relative contribution of asymptomatic per-
sons to the reservoir of genetic resistance. Asymptomatic
infections provide a parasite reservoir that contributes to
malaria transmission even in areas of low or unstable
transmission intensity [21-26], but uncertainty exists
regarding the role of asymptomatic infections in the trans-
mission of genetic changes conferring drug-resistance.
Genetic markers of drug resistance in P. falciparum, in-
cluding pfcrt K76T haplotypes and pfmdr1 amplification,
[27] are associated with decreased parasite fitness and
impaired within-host growth [28]. Less fit parasites may
be more likely to produce low parasitemia infections that
remain asymptomatic. Persistent carriage of resistant para-
sites in asymptomatic populations is unlikely in situations
where multiclonal infections are common, given that more
fit parasites with a single copy of pfmdr1 are likely to out-
compete less fit parasites with multiple copies of pfmdr1.
However, asymptomatic carriage could be favoured in
relatively low transmission settings such as those included
in this study where host immunity may be insufficient to
clear infection and mono-infection with a single resistant
clone may be common, particularly if de-amplification of
pfmdr1 CN is rare. In addition, compensatory mutations
that decrease the fitness cost of pfmdr1 amplification may
allow drug-resistant clones to persist during multiclonal
infections. The persistence of drug-resistant infections
[29], including multicopy pfmdr1 infections [30], may also
be favoured by higher gametocyte carriage that appears
to increase their transmission potential relative to drug-
sensitive, wild-type infections.
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the prevalence of elevated pfmdr1 CN and the pfcrt
K76T allele in three previously unstudied remote or
conflict-affected populations living along Myanmar’s
borders with India, China and Thailand. This study
investigated the contribution of subclinical infections to
the epidemiology of genetic resistance by testing the
a priori hypothesis that resistance gene prevalence would
be higher among isolates collected during active popula-
tion screening compared to isolates collected from febrile
clinical patients. The findings have been situated in con-
text by conducting a systematic review of in vivo, in vitro,
and molecular resistance studies in Myanmar and border
regions of neighbouring countries. Resistance study loca-
tions were mapped relative to areas of recent civil con-
flict to test the second a priori hypothesis that politicallyFigure 1 Anti-malarial, drug-resistance studies in Myanmar and neigh
locations of in vivo, in vitro and molecular studies conducted between 1996
circles (n = 13 sites). Studies reporting prevalence of pfmdr1 copy number a
on the x-axis of the bar figures, in order of data collection year. Previous m
from neighbouring countries appear on the country-wide map. Locations o
shading. See manuscript text for additional information on displaced villag
abstracted prevalence estimates.unstable areas would be under-represented among resist-
ance studies in Myanmar.
Methods
Study sites and participants
Between February 2009 and January 2010, three commu-
nity based organizations established 13 surveillance sites
in three remote regions of Myanmar: Karen State, Kachin
state, and an area spanning the border of Chin State,
Myanmar and Mizoram State, India (Figure 1). Popula-
tions were selected based on history of malaria burden,
feasibility of sample collection, and past exclusion from
other surveillance programmes due to inaccessibility or
security concerns. Samples were collected by community
health workers (CHWs) and VHWs who extend the




























































































































































bouring countries, by region and year. Blue squares represent the
and 2009; locations of the current study (2008–2009) appear as red
mplification or pfcrt K76T haplotypes are numbered on the map and
olecular studies from Myanmar appear in insets; molecular studies
f villages forcibly displaced between 2008–2011 are indicated by red
es, and Additional file 1 for a complete list of molecular studies and
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shaded areas of the map in Figure 1 indicate the locations
of villages displaced since 2008 in Karen and Kachin
States, where armed conflict was ongoing or imminent,
respectively. Sites in border areas of Chin State were
located in areas where exposure to human rights viola-
tions were widespread [31].
Oral, informed consent was obtained from all parti-
cipants. Ethical approval for the study was obtained
from relevant authorities at each community based
organization; Johns Hopkins School of Public Health
Committee on Human Subjects approved secondary
analysis of the data.
Samples were collected during routine malaria
programme activities modified to assess the prevalence
of non-P. falciparum species using PCR and validate the
use of a P. falciparum-specific, histidine-rich protein 2
(HRP-II) based rapid diagnostic test (RDT, ParacheckW,
Orchid Biomedical Systems, Goa, India) in the setting
of clinical diagnosis and population-based screening.
CHWs collected blood spots from consecutive clinic
patients with self-reported fever and from a sub-
sample of villagers participating in routine bi-annual
community malaria prevalence surveys [18,19,32]. All
participants were tested for P. falciparum using the RDT
and had a blood sample collected on Whatman 903
Protein SaverW cards. The sampling protocol for the
programme evaluation was designed to yield approxi-
mately n = 540 Pf-positive samples: n = 80 from febrile
clinical patients and n= 100 from villagers participating
in active screenings in each of three regions. Based on
a real-time polymerase chain reaction (RT-PCR) budget
sufficient to test 2,100 samples, the target sample num-
ber for each region was set at 700 (500 screening and
200 clinical). Because historical programme data indi-
cated that P. falciparum population prevalence in each
region was consistently below 15-20%, the number of
screening participants was increased to yield approxi-
mately 100 P. falciparum -positive isolates. False-positive
RDT results due to persistent HRP-II antigenaemia were
expected to approximately offset false-negative RDT
results due to low sensitivity in the setting of low parasi-
taemia infection.
With an expected RDT-positivity rate of approximately
40%, sample collection was anticipated to yield ~80
P. falciparum -positive isolates from 200 febrile clinical
patients in each region. When preliminary results sug-
gested a lower RDT positivity rate (18-33%), the period
of sample collection was extended from two to six
months. PCR was performed on all RDT-positive samples
and a region-specific fraction of RDT-negative samples
from screening participants (22-34%) and clinic patients
(17%-70%) sufficient to yield approximately 500+ 200=
700 samples for RT-PCR from each region.DNA extraction and Plasmodium falciparum detection by
real-time PCR
Following an existing protocol [33], DNA was extracted
from dried blood samples using a commercial, 96-well,
DNA extraction kit from Promega (Madison, Wisconsin,
USA). For each sample, DNA from three 5-mm punches
(equivalent to approximately 25 μL whole blood) was
extracted and concentrated four-fold by glycogen-acetate
precipitation. Plasmodium falciparum DNA was identi-
fied using a validated TaqMan multiplex real-time PCR
assay for P. falciparum 18 s ribosomal DNA [33], a mo-
lecular method for P. falciparum detection that has sensi-
tivity and specificity comparable to nested PCR protocols
[34,35]. Isolates were considered P. falciparum-positive if
18 s PCR end-cycle fluorescence exceeded 300 RFU. All
PCR reactions were run in 384-well plates on the Bio-Rad
CFX384 Real-Time System (Bio-Rad, Hercules, CA, USA).
Primers and probes for TaqMan PCR were synthesized by
Integrated DNATechnologies (Coraville, Iowa, USA).
pfmdr1 copy number determination by multiplex
real-time PCR
pfmdr1 copy number was determined using a modification
of previous assays [13,36]. Primers and a FAM-labelled
probe specific for pfmdr1, plus primers and a Texas Red-
labelled probe specific for P. falciparum β-tubulin, were
amplified as a multiplex. Each reaction included β-tubulin
primers (100nM), β-tubulin probes (100nM), pfmdr1 pri-
mers (300nM), pfmdr1 probes (200nM), Bio-Rad iQ
Multiplex Powermix (1x), and 5 μL DNA, in a total reac-
tion volume of 10 ul.
Amplification curves were analysed and cycle thres-
hold (Ct) values determined using Bio-Rad CFX Man-
ager software. pfmdr1 copy number was calculated using
the predictive efficiency method [36], which corrects the
ΔΔ Ct method for differences in amplification efficiency
between the reference gene and gene of interest. Ge-
nomic DNA from P. falciparum strains 3D7, D10, Dd2
were included as internal controls on each 384-well plate
(MR4, Virginia, USA). These strains are known to have
one, one, and three to four pfmdr1 copies, respectively.
Genomic DNA from 7C424, a strain previously deter-
mined to have two copies of pfmdr1, was also used to val-
idate the assay. Mean copy number estimates were 1.15
for D10 (SD=0.20, 32 repeats), 2.31 for 7C424 (SD=
0.42, 35 repeats), and 2.98 for Dd2 (SD=0.39, 35 repeats).
All reactions were run in triplicate and individual
replicates were rejected if they did not display exponen-
tial kinetics. The precision of pfmdr1 CN estimates was
calculated for a given isolate as the ratio of the range
(maximum–minimum) divided by the mean of isolate-
specific replicates (n = 2 or 3). Copy number estimates
were repeated if the difference between replicates was
greater than 50% of the mean estimate, or if the average
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than 34. CN estimates were considered invalid if the
variance remained greater than 50% of the mean estimate
or Ct remained greater than 34 after the third repeat.
In the course of the study, a higher proportion of sub-
clinical screening isolates than clinical isolates produced
invalid CN estimates. A post-hoc analysis explored the
reasons for this discrepancy and assessed the technical
feasibility of using filter paper blood samples to estimate
pfmdr1 gene copy number in isolates from a predomin-
antly asymptomatic population with relatively low per-
ipheral blood parasite concentrations. Recent evidence
suggests that the volume of blood available from filter-
paper samples may be insufficient to achieve highly ac-
curate PCR results, particularly when parasitaemia level
is low [26]. Current methods to assess gene copy number
may be particularly sensitive to DNA concentration,
because copy number is a function (ratio) of two quanti-
tative amplification thresholds. Past studies assessed
pfmdr1 CN using filter paper-based samples collected
from febrile clinical patients [20]; this study explored the
feasibility of extending these methods to predominantly
asymptomatic infections among active screening partici-
pants, and whether the variance in CN estimates was
associated with parasite DNA concentration. The preci-
sion of pfmdr1 CN estimates was plotted against cycle
threshold (Ct) values, a proxy for parasitaemia level. Ct
values are inversely proportional to the log DNA concen-
tration in a given isolate, and a three-cycle increase in
the Ct corresponds to approximately a 10-fold decrease
in relative concentration of P. falciparum DNA.
Detection of pfcrt polymorphisms by multiplex
real-time PCR
Plasmodium falciparum-positive samples were analysed
for wild-type pfcrt and pfcrt alleles carrying the K76T
polymorphism, using validated primers and probes for
the CVIET and CVMNK haplotypes [37]. Each PCR reac-
tion included forward and reverse primers for the pfcrt
gene (200nM), a Texas Red-labelled probe specific for
the wild-type allele (200nM), a FAM-labelled probe spe-
cific for the K76T allele (200nM), Bio-Rad iQ Multiplex
Powermix (1x), and 5 μL DNA, in a total reaction volume
of 10 μl. Average fluoresence of the last five PCR cycles
(“end-cycle fluoresence”) was used to determine the pres-
ence or absence of the wild-type and K76T polymorph-
isms. Genomic DNA from the CQ-sensitive D10 and
CQ-resistant Dd2 strains were included on each 384-well
plate as references. All samples were run in duplicate
and criteria for identifying CQ-sensitive parasites were
chosen for high specificity. Samples were identified as
carrying the wild-type CQ-sensitive allele if both replicates
had end-cycle fluorescence greater than 5% of the range
between negative and positive controls.Statistical analysis
Data was entered into an ACCESS database using range
and consistency checks. Statistical analyses were per-
formed using Stata 12.1. Standard errors were corrected
for clustering of the data by village cluster (n = 13).
Systematic review of Plasmodium falciparum anti-malarial
resistance studies in Burma/Myanmar and its border
regions
PubMed and Google Scholar were searched for clinical,
in vitro, and molecular studies evaluating resistance of
Plasmodium falciparum to CQ, MQ and ACTs in
Myanmar and neighbouring countries. Search terms
included “falciparum”, “resistance”, “efficacy”, “Burma”,
“Myanmar”, “Thailand”, “China”, “India”, “Bangladesh”,
“pfmdr1”, “pfcrt”, “chloroquine”, “mefloquine”, “lume-
fantrine”, “artemisinin combination therapy”, “anti-
malarial”; and minor variations on these terms. This
search generated 860 publications. Reference lists of
studies identified in the primary search were searched, as
was data from public sources, including WHO Southeast
Asia Region and country-specific publications of the
WHO and respective Ministries of Health. The review
included reports from Bangladesh, India and China if
P. falciparum isolates were collected from areas border-
ing Myanmar, and restricted the review to reports pub-
lished in English after 1995. Only observational and
clinical intervention studies and related review articles
were included; studies that reported only basic science or
methods-oriented findings were excluded. Eighty-two
manuscripts met these inclusion criteria. Reports were
reviewed for clinical efficacy (failure rates, recrudes-
cence/re-infection, parasite clearance time), in vitro sus-
ceptibility data (i e, IC50s) and molecular markers
associated with resistance (pfmdr1 SNPs, pfmdr1 amplifi-
cation, and the K76T pfcrt mutation) to CQ and MQ
monotherapy, and any ACT. Figure 1 shows locations of
all studies meeting criteria for this review (blue squares);
molecular studies are numbered for reference to the
adjacent bar graphs and are listed in Additional file 1.
Resistance study locations were determined from published
manuscripts and by contacting study authors. Unstable
areas of Karen and Kachin States were identified based
on evidence of forced displacement of villages since 2008
provided by the Thai-Burma Border Consortium [38] and
a community-based organization providing humanitarian
assistance in Kachin State (Figure 1).
Results
Active screening of 4,591 out of 14,982 people living
in 13 village-clusters identified 157 isolates positive for
P. falciparum 18 s DNA, and sequential testing of 988
febrile clinical patients identified 133 P. falciparum-
positive isolates (Table 1).
Table 1 Study population characteristics
Study Region
Karen Kachin Chin
Number of study sites 4 5 4
Population 6176 4170 4636 (Total population: 14,982)
Percentage of study participants % (number)










Age <5 years 459 284 201 17% (944) 99% (938) 13% (121) 34% (327) 5% (49)
5-15 years 717 662 522 33% (1,901) 99% (1,881) 15% (281) 36% (684) 7% (138)
>15 years 996 947 873 50% (2,816) 97% (2,752) 13% (371) 34% (964) 4% (99)
Female 1,152 1118 801 54% (3,071) 99% (3,038) 12% (375) 35% (1,070) 4% (136)
Asymptomatic
screening participants
1,900 1,639 1,178 80% (4,717) 97% (4,591) 9% (430) 32% (1,507) 3% (157)
Febrile clinical patients 536 254 427 20% (1,217) 81% (988) 35% (343) 42% (506) 11% (133)
Total participants 2,436 1,893 1,605 5,934 94% (5,579) 14% (773) 34% (2013) 5% (290)
RDT rapid diagnostic test; PCR polymerase chain reaction; Pf Plasmodium falciparum.
a The second round of clinic treatment books in Karen sites were not available to link RDT results to filter-paper blood spots (n = 228). All filter samples were
eligible for selection for PCR.
b Cells do not add to 5,934 due to missing age and sex data; percentages may not add to 100% due to rounding.
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Of 290 P. falciparum-positive isolates, 173 (59.6%) were
successfully genotyped for pfmdr1 copy number (Table 2).
Thirty-nine percent (18/46) of samples from Kachin
State, 62% (115/186) from Chin State, and 80% (40/50)
from Karen State yielded acceptable copy numberTable 2 Pfmdr1 copy number (CN) among subclinical and clin
pfmdr1
1 2
Karen State (n = 40) 33 6
Clinic 21 0
Screening 12 6
Kachin State (n = 18) 16 2
Clinic 5 1
Screening 11 1
Chin-Mizoram (n= 115) 104 11
Clinic 76 6
Screening 28 5
Screening vs clinicalTotal (n = 173) 153 19
Clinic 102 7
Screening 51 12
Anti-malarial treatment Total (n = 168) 148 20
No treatment in past 8 weeks 117 17
Treatment in past 8 wks 31 3
aCIs adjusted for clustering within study site (n = 13).
bOR= odds of pfmdr1 amplification among screening participants/odds of amplifica
c OR = odds among participants reporting treatment in past 8 weeks/odds among testimates. Copy number ranged from 0.72 to 3.70. 11.6%
(19/173, 95%CI = 2.7-20.4) of samples had >1.5 copies
and 4.6% (8/173) had >2 copies. The proportion of iso-
lates with copy number >1.5 (95% CI) was 9.6% in Kachin
State, 11.1% in Chin State, and 17.5% in Karen State
(Table 2 and Figure 2). Isolates from population-ical isolates from three regions of Myanmar 2008–2009
CN % CN >1.5
3 4 (95% CI)a OR (95% CI)a
0 1 17.5 (0–54.3)
0 0 0.0
0 1 35.0 n/a
0 0 9.6 (0–31.6)
0 0 16.7
0 0 8.3 0.5 (0.0–7.8)b
0 0 11.1 (0–32.1)
0 0 7.3
0 0 15.2 2.3 (1.1-4.7)b
0 1 11.6 (2.7-20.4)
0 0 6.4
0 1 20.3 3.7 (1.1-12.5)b
0 1
0 1 12.7
0 0 8.8 0.7 (0.1-3.1)c
tion among febrile clinical patients.










































































Figure 2 Scatterplots and boxplots of pfmdr1 copy number estimate precision and Plasmodium falciparum beta-tubulin PCR cycle
thresholds (Ct) for febrile clinical patients (grey circles and boxplots) and active screening participants (empty circles and boxplots) A:
The scatterplots demonstrate precision of pfmdr1 copy number (CN) estimate (y-axis) diminishes as DNA concentration (x-axis) decreases among
active screening participants (bottom panel) and febrile clinical patients (top panel). The mean cycle threshold and mean precision of pfmdr1 CN
is indicated by the black point on each scatterplot. A three-cycle increase in the Ct corresponds to a 10-fold decrease in relative concentration of
Pf DNA. Pfmdr1 precision is calculated as the range/mean for each isolate, with higher values indicating lower precision. The standard deviation
of pfmdr1 CN estimates was 0.200 for clinic patients and .516 for screening participants (not shown) B: Boxplots display the distribution of DNA
concentration (top panel) and pfmdr1 CN precision. Boxes represent inter-quartile ranges (IQR); whiskers represent the value of [upper/lower
quartile +/− (IQR*1.5)]. Screening participants had lower DNA concentration and less precise estimation of pfmdr1 CN.
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febrile clinical patients to have elevated pfmdr1 copy
number (OR 3.7, 95% CI 1.1-12.5). There was no differ-
ence in pfmdr1 amplification between participants who
did and did not report taking anti-malarial treatment in
the previous eight weeks.Pf DNA concentration and precision of pfmdr1 copy
number determination
Of all CN estimates calculated, including repeat assays, 83
of 157 asymptomatic screening isolates (55%) and 23 of
133 clinic isolates (17%) had range:mean ratios greater
than 0.5 and/or mean Pf b-tubulin Ct values greater than
34, indicating a Pf DNA concentration insufficient to es-
timate pfmdr1 CN. Precision of pfmdr1 copy number
decreased with decreasing P. falciparum DNA concentra-
tion (Figure 2). The mean P. falciparum DNA concentra-
tion was lower for screening samples than for clinical
samples and the precision of copy number estimates was
lower overall for screening samples (Figure 2).pfcrt wild-type and K76T alleles
Multiplex PCR detected the wild-type pfcrt allele in 11
of 290 isolates (Table 3). Eight of 186 isolates from sur-
veillance sites in Chin State carried the sensitive allele,
as did three of 46 from sites in Kachin State; the sensi-
tive allele was not identified in any of the 57 samples
from Karen State. Twenty isolates failed to amplify ei-
ther the sensitive or the K76T allele. Prevalence of the
wild-type pfcrt allele was similar in isolates from active
screening participants and febrile clinical patients, and
did not vary by report of anti-malarial treatment in the
previous eight weeks.Systematic review
See Figure 3 and Additional file 1 for results of the brief
systematic review of in vivo, in vitro and molecular resist-
ance studies. Half of the 82 resistance studies meeting in-
clusion criteria were conducted in western Thailand,
including all but two studies of pfmdr1 CN. One study
of pfmdr1 CN from Myanmar was identified, conducted
Table 3 Pfcrt genotypes among subclinical and clinical isolates from three regions of Myanmar 2008-2009
No. (%)
Resistanta WT K76 OR (95% CI)a
Karen State (n = 58) 58 (100) 0 (0.0)
Clinic 27 (100) 0 (0.0)
Screening 31 (100) 0 (0.0) n/a
Kachin State (n = 46) 43 (93.5) 3 (6.5)
Clinic 12 (100) 0 (0)
Screening 31 (91.2) 3 (8.8) n/a
Chin-Mizoram (n= 186) 178 (95.7) 8 (4.3)
Clinic 88 (93.6) 6 (6.4)
Screening 90 (97.8) 2 (2.2) 0.3 (0.1-1.7)
Screening vs clinic Totalb (n = 232) 221 (95.3) 11 (4.7)
Clinic 100 (94.3) 6 (5.6)
Screening 121 (96.0) 5 (4.0) 0.7 (0.2-2.2)
Anti-malarial treatment Totalc (n = 232) 221 (95.3) 11 (4.7)
No treatment in past 8 weeks 174 (95.6) 8 (4.4)
Treatment in past 8 weeks 47 (94.0) 3 (6.0) 1.4 (0.4-5.0)
aResistant genotypes: 259 amplified K76T; n = 20 isolates that failed to amplify either K76T or wild type K76 were assumed to harbour a resistant genotype
(eg SVMNT). Dropping these 20 observations from the analysis does not qualitatively modify the results.
bStandard errors corrected for clustering within village cluster (n = 13).
cTotals exclude Karen State given apparent fixation (100%) of the K76T allele.
Percentages may not sum to 100 due to rounding.
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and molecular studies did not overlap with areas of
instability, indicated forcibly displaced villages (red
shading) on the map in Figure 1.
Discussion
This study demonstrates the feasibility of incorporating
a network of health workers affiliated with community-
based organizations into strategies for molecular surveil-
lance of malaria resistance in remote and unstable areas
of Myanmar, including priority Tier 1 and Tier 2 areas
at high risk for the spread of delayed parasite clearance.
This surveillance network can accelerate the assessment
of artemisinin resistance and delayed parasite clearance
once genetic markers are identified. Myanmar’s ecologic,
ethnic and political diversity, coupled with patchwork ac-
cess to malaria control services and quality anti-malarials
creates a mosaic of selective drug pressure, and this study
provides a preliminary glimpse of patterns emerging over
time and place in remote areas of the country, including
areas directly across the border from western Thailand
where delayed parasite clearance was recently confirmed.
The prevalence of pfmdr1 amplification was relatively
low (12-19%) across the three border regions included in
the current study; and only a single isolate had a CN of
three or more. Results from Karen State contrast with
recent studies documenting elevated CN in at least 40%of isolates [9] with a mean CN of 2.9 (SE 1.4) [39] among
refugee, migrant and cross-border populations in Thailand
(Figure 1). Findings from Kachin State contrast with a re-
cent study in Laiza that found no pfmdr1 amplification in
171 P. falciparum isolates [40,41], but is consistent with a
study conducted in 2004 in nearby counties of Yunnan
province [42]. The systematic review failed to identify pre-
vious studies of pfmdr1 CN along the borders with India
and Bangladesh to compare to the 11% prevalence esti-
mated for that region.
Multiple factors likely contribute to the observed vari-
ation in pfmdr1 amplification documented within and
between populations living in Myanmar and across its
borders in neighbouring countries. Little is known about
host response in populations in Myanmar [24], but
host immunity is likely to be relatively more robust
given higher transmission intensity compared to western
Thailand and Yunnan, where migrants from Myanmar
account for the majority of infections [19,43-46]. Select-
ive drug pressure also varies substantially due to differ-
ences in access to quality diagnosis and treatment.
Populations included in the present study live in areas
that government and international NGO health services
largely fail to reach, and community based organiza-
tions are unique providers of malaria control interven-
tions. The low prevalence of pfmdr1 amplification in
Karen study sites may be due in part to these malaria
Myanmar (n=12; 15% of studies: nine in vivo, one in vitro and one molecular; the MARC 
reviews unpublished findings)
• Direct evidence of artemisinin resistance is lacking, although preliminary in vitro data from southern 
Myanmar suggests emerging tolerance to AL and DHQ [7]
• In published in vivo studies, ACTs remain highly efficacious (clinical failure rates below 3%) [60-63]
• MQ monotherapy is less effective in clinical trials, with higher 42-day failure rates than ACT. [62] In 
vitro resistance to MQ appears to be highest near the border with Thailand [64]
• Molecular studies are limited. A single study from Laiza Township, Kachin State found all P. falciparum 
isolates carried the mutant K76T allele (CVIET); all isolates harboured a single copy of pfmdr1 [39]
________________________________________
Western Thailand (n=41; 50% studies)
• Genetically-determined resistance to ART, measured by average parasite clearance time and the 
proportion slow-clearing infections during ART treatment, was recently confirmed in western Thailand 
[1]
• Clinical efficacy of MAS3, the standard first line treatment for uncomplicated P. falciparum infections, 
remains high but has declined slightly since 1995 [65]
• Resistance to MQ monotherapy emerged shortly after introduction in 1985 [66]. Introduction of MAS3 
may have slowed or reversed the decline in clinical efficacy of MQ [67]
• pfmdr1  amplification is associated with resistance to MQ, ART monotherapy, and MAS combination 
therapy. [9, 10] The prevalence of pfmdr1 amplification has increased since 1996, [9, 10, 13, 65, 
68-70] but does not appear to explain increasing tolerance to ACTs over time [1, 65]
• CQ resistance is widespread and multiple studies document fixation of the pfcrt K76T mutation. [9, 
13, 68, 71].
________________________________________
Yunnan Province, China (n=6, 7% of studies)
• Unpublished studies suggest low-level clinical resistance to ART monotherapy has emerged in south-
ern Yunnan Province [7], with two- to three-fold increases in resistance parameters between 1988 and 
1999. [72]
• In western Yunnan, in vitro resistance to CQ decreased from 100% in 1982 to 83% in 2003 [73], 
although in 2006 40% of infections exhibited in vivo resistance to CQ. [73] 90-92% of isolates carry the 
pfcrt K76T mutation [40, 74]
• A single study reported Pfmdr1 amplification in 9.4% of isolates from southern Yunnan in 2004 [40]
________________________________________
Northeast India (n=11, 13% of studies)
• Resistance to MQ is rare [75]and ACT appears to be nearly 100% clinically effective [76]
• CQ resistance is prevalent in north-east India, with high treatment failure rates observed in states 
bordering Myanmar: 60% in Mizoram, 29% in Nagaland, 80% in border districts of Arunchai Pradesh
• pfcrt K76T mutations are at fixation. [77] Both CVIET and SVMNT haplotypes are prevalent  [78]
• The literature review found no published studies on pfmdr1 amplification in this region
________________________________________
Eastern Bangladesh (n=10, 12% of studies) 
• MAS and AL remain highly efficacious in the Chittagong Hill Tracts, an area bordering Rakhine State, 
Myanmar, with 42-day PCR-corrected efficacy rates of 100% and 97%, respectively [79]
• P. falciparum isolates from the Chittagong Hill Tracts were more susceptible to CQ and ART in vitro 
compared to isolates from the Thai-Myanmar and Thai-Cambodia borders [80]
• CQ resistance is well established [79, 81] and over 95% of isolates carry the pfcrt K76T mutation [82] 
• The literature review found no published studies on pfmdr1 amplification in this region
Figure 3 Systematic review of in vivo, in vitro, and molecular resistance studies in Myanmar and neighbouring countries, 1996–2009
[1,7,9,10,13,39,40,60-82].
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ectly observed mefloquine-artesunate that may modify
selective pressure for pfmdr1 amplification [47].
The pfcrt K76T mutation is a highly predictive marker
of CQ resistance [48]. Replacement of K76T mutants
with wild-type parasites following withdrawal of drug
pressure has forecast the return of CQ clinical efficacy
[49,50] and some authors have proposed tracking this
mutation to identify populations in which CQ could be
used as partner drugs in ACT [51]. The very low preva-
lence of wild-type pfcrt in the present study is consistentwith data from nearby areas and suggests ongoing select-
ive pressure for CQ resistance. Although decades have
passed since CQ was officially recommended by Myanmar
or any of its neighbours for the treatment of P. falciparum
infection, CQ remains the treatment of choice for P. vivax
and presumptive malaria. The use of RDTs capable of
identifying both P. falciparum and P. vivax species may
modestly diminish this selective pressure, but tracking the
prevalence of wild-type pfcrt is likely to remain a low pri-
ority for resistance surveillance for the next several years.
However, pfcrt could become an important genetic marker
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CQ to ACT in response to the recent emergence of
CQ-resistant P. vivax in western Thailand [52,53].
Consistent with the a priori hypothesis, the preva-
lence of elevated pfmdr1 CN was higher among isolates
obtained from active screening participants than from
isolates obtained from febrile clinical patients. Resist-
ance surveillance currently relies on samples obtained
from clinically symptomatic malaria patients; contain-
ment efforts may need to more aggressively target sub-
clinical infections that could serve as a reservoir for the
spread of drug resistance if future studies validate an as-
sociation between subclinical infection and resistance
alleles. However, there are several reasons to approach
this finding with caution. First, to the authors’ knowledge
this is the first study to evaluate pfmdr1 CN in a predom-
inantly asymptomatic population. Zhong et al. [54]
found no difference between symptomatic and asymp-
tomatic study volunteers in Kenya in the frequency of
pfmdr1 point mutations, or of the K76T mutation of
pfcrt. Second, consistent with Zhong et al. the current
study found no difference in K76T mutation prevalence
between screening and clinical participants, though
prevalence of wild-type pfcrt was low in each region and
results may be confounded by ongoing CQ drug pressure
as described above. Third, a robust empirically derived
conceptual model is lacking to adequately capture the
complex interactions between transmission intensity,
host immunity, drug pressure, fitness cost, compensatory
mutations, clonality of infection, de-amplification [27,55]
and other factors expected to influence the relative
prevalence of resistant and wild-type parasites in clinical
and asymptomatic infections. Clonality of infection is
likely to play an important role, as described above, but
the prevalence of monoclonal infection in Myanmar is
poorly quantified. A single study from central Myanmar
documented mono-infection in 32% of clinical isolates
[56], but the relevance of these data to asymptomatic
populations in border regions is unclear. The final reason
to interpret with caution the association between sub-
clinical infection and genetic resistance is the high vari-
ance of pfmdr1 CN estimates found among screening
participants that led to the exclusion of 55% of samples.
Future studies are needed to validate the accuracy of
pfmdr1 CN estimates based on filter-paper blood samples
collected from subclinical populations. Despite these
caveats, findings presented here highlight the need to
conduct additional studies on the contribution of sub-
clinical infection to the epidemiology of drug-resistant
malaria.
Although mosquitoes and migrating humans fre-
quently carry parasites across international boundaries,
it is not clear whether findings from neighbouring coun-
tries should be extrapolated to populations living inMyanmar. Individuals seeking care from border clinics
by definition have access to diagnostic and treatment
protocols and other resources of neighbouring countries
that may differ substantially from those available in re-
mote and conflict-affected areas of Myanmar. Add-
itional studies are necessary to determine the appropriate
geographic scale for monitoring the spread of drug
resistance.
Systematic review of in vivo, in vitro and molecular
resistance studies from Myanmar and its border regions
identified relatively few data from populations living
inside the country, particularly in Tier 1 and 2 areas
of highest priority for resistance containment. The
paucity of available information is consistent with out-
put from the under-developed health research capacity
in the country as a whole: Myanmar ranks 218th out of
224 countries in number of publications in medicine per
capita (0.4 per 100,000 people) [57]. Armed conflict and
large-scale population displacement are established
causes of disruptions in health services and disease sur-
veillance [58], and can result in “stability bias”, defined
as the “systematic under-sampling of populations and
health threats in contexts of conflict and instability”
[59]. The lack of overlap between previous resistance
study locations and displaced populations in Myanmar
documented in the present study suggests that stability-
bias may contribute to within-country distribution of
evidence available for resistance surveillance. The ana-
lysis presented here highlights areas with documented
population displacement, but does not capture all con-
flict and human rights violations experienced by other
communities. For example, approximately 92% of house-
holds in Chin State may experience forced labour [31]
and other human rights violations that have been asso-
ciated with prevalent malaria infection [32]. The instabil-
ity of sites participating in this study was tragically
validated by violent events since data collection com-
pleted in 2009: one Karen site and all Kachin sites were
displaced due to military attacks. Some health workers
have continued to implement disease control interven-
tions in relocated areas; and they remain willing to
participate in resistance surveillance activities. One
community-based organization is establishing a site to
monitor parasite clearance time.
There were several important limitations to this study.
Twenty P. falciparum isolates did not amplify either wild
type or K76T alleles and it is not possible to exclude the
presence of other rare resistance alleles such as SVMNK
that were not assessed. None of these twenty isolates
produced valid copy number estimates, and they do not
modify our primary conclusions that pfmdr1 amplifica-
tion may be more common among subclinical infections,
and that that wild type pfcrt remains rare in these three
regions of Myanmar.
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subclinical infections was low for 44% of isolates, and 16%
of isolates had DNA concentrations below the lower limit
of reliable copy number determination, even after four-fold
DNA concentration with glycogen-acetate precipitation. As
noted above, future studies are necessary to validate the
use of filter-paper samples to estimate gene CN from low-
parasitaemia isolates such as those collected from subclin-
ical infections. This study was not designed to elucidate
the mechanisms or relative contributions of factors influ-
encing the prevalence of resistant parasites in subclinical
populations. For example, clonality of infection was not
determined and parasite DNA from prior infections was
unavailable to distinguish re-infection from recrudescence.
The cross-sectional design limits causal inference, and
findings related to measures of association should be
considered preliminary, as noted above. Study partici-
pants lived in areas where quality malaria control ser-
vices were ongoing for three to 8 years, and findings may
not apply to intervention-naïve populations. Samples
were collected in 2008–2009 and may not reflect the
prevalence of resistance markers in 2012. For example,
areas of western Thailand north of Maesot, immediately
across the border from one of the present study sites,
experienced a sharp rise in the proportion of slow-
clearing parasites between 2008–10 [1,2].
The number of P. falciparum-positive isolates (290)
was lower than anticipated by the study design (540)
despite screening 4,591 villagers and 988 febrile clinical
patients. Logistical constraints delayed data collection in
Karen and Kachin areas until the lower-transmission,
dry-season months of February and March, with extended
clinical sampling through June. The study was conducted
in areas of active malaria control, and the success of these
programmes likely contributed to the low prevalence of
P. falciparum and low RDT positivity rates. The smaller
than anticipated number of P. falciparum positive samples
limited the precision of estimates of genotype prevalence
in subclinical and clinical infections, and poor statistical
power precluded comparisons across geographic regions.
Nevertheless, the number of isolates available for geno-
typing compares favourably to studies conducted in more
stable areas, and data from individuals with subclinical
P. falciparum infections is unique among published
studies from this region.
Conclusions
Networks of community-based health organizations can
and should contribute to molecular surveillance of anti-
malarial drug resistance in remote and unstable areas of
Myanmar, including priority Tier 1 and 2 areas at greatest
risk for spread of delayed parasite clearance. Desiccated
filter paper facilitates accurate estimation of pfmdr1 CN
among febrile clinical isolates and extends the potentialgeographic range of genetic resistance surveillance, but
further study is necessary to validate the use of filter
paper in the setting of subclinical infections with low
parasite DNA concentrations. The increased risk of
pfmdr1 amplification observed among active screening
participants hints at a plausible and potentially important
contribution of subclinical infection to resistance trans-
mission, but further study is necessary to elucidate the
epidemiology of drug resistance among predominantly
asymptomatic populations. The consistently low preva-
lence of wild-type pfcrt alleles, documented in this and
other studies, is consistent with persistent CQ drug pres-
sure that is unlikely to diminish until treatment protocols
specify CQ-free regimens for P. vivax infections. A sys-
tematic review of resistance studies revealed a dearth
of data from Myanmar, particularly from areas recently
experiencing armed conflict and forced displacement.
Marginal populations, such as those participating in this
study, should be represented in future resistance surveil-
lance efforts, particularly once genetic markers of delayed
parasite clearance are identified. Failure to include these
at-risk areas may compromize global efforts to monitor
and contain the spread of resistance.Additional file
Additional file 1: Brown. Supplementary Appendix 1.docx. Peer-
reviewed cross-sectional studies reporting prevalence estimates for
pfmdr1 copy number or pfcrt K76T haplotypes in Burma and adjacent
areas of neighboring countries, 1996-2009. Summarizes cross-sectional
molecular studies of antimalarial drug resistance included on the map in
Figure 1.
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